EloraTZP Explained: Why Amylin + GIP/GLP-1 Is the Next Metabolic Research Frontier
New Phase 2b EloraTZP data combine eloralintide's amylin pathway with tirzepatide's GIP/GLP-1 activity. Here's what the 48-week results show and what Phase 3 must answer.
Retatrutide Phase 3 Results: What the New TRIUMPH-2 Data Show
Detailed Phase 3 TRIUMPH-2 results put retatrutide back in focus. Here is what the weight-loss and A1C data show, how the triple agonist works, and the key limitations.
Retatrutide vs Semaglutide and Tirzepatide: What the New Phase 3 Data Really Show
New TRIUMPH-2 Phase 3 data add important evidence for retatrutide. Here is what the results show, why cross-trial comparisons are limited, and what direct comparison studies may answer next.